Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors Jul 09, 2021 8:00am EDT
Molecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare Conference Jul 06, 2021 8:00am EDT
Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Cancer Research (AACR) Virtual Annual Meeting I Apr 12, 2021 7:00am EDT
Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering Feb 18, 2021 7:30am EST
Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer Feb 11, 2021 7:30am EST
